首页> 外文期刊>Radiation oncology >Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogr
【24h】

Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogr

机译:宫颈癌根治性子宫切除术后强度调节放疗与三维共形放疗联合基于奈达铂的化疗的比较:结局,并发症和剂量体积组织学的比较

获取原文
           

摘要

Background The purpose of this study is to report our clinical outcomes using intensity-modulated radiation therapy (IMRT) for adjuvant treatment of cervical cancer, compared with three-dimensional conformal radiation therapy (3DCRT), in terms of tumor control, complications and dose-volume histogram (DVH) parameters. Methods Between March 2008 and February 2014, 62 patients were treated with concurrent nedaplatin-based chemotherapy and whole-pelvic external beam radiation therapy (RT). Of these patients, 32 (52 %) received 3DCRT and 30 (48 %) received IMRT. Results The median follow-up periods were 40 months (range 2–74 months). The 3-year overall survival rate (OS), locoregional control rate (LRC) and progression-free survival rate (PFS) were 92, 95 and 92 % in the IMRT group, and 85, 82 and 70 % in the 3DCRT group, respectively. A comparison of OS, LRC and PFS showed no significant differences between IMRT and 3DCRT. The 3-year cumulative incidences of grade 2 or higher chronic gastrointestinal (GI) complications were significantly lower with IMRT compared to 3DCRT (3 % vs. 45 %, p?340 mL (3 % vs. 45 %, p?
机译:背景技术这项研究的目的是在肿瘤控制,并发症和剂量方面,报告与三维共形放射治疗(3DCRT)相比,采用强度调制放射治疗(IMRT)辅助治疗宫颈癌的临床结果。体积直方图(DVH)参数。方法在2008年3月至2014年2月期间,对62例患者同时进行了基于奈达铂的化疗和全盆腔体外束放射治疗(RT)。在这些患者中,有32名(52%)接受了3DCRT,有30名(48%)接受了IMRT。结果中位随访期为40个月(2-74个月)。 IMRT组的三年总生存率(OS),局部区域控制率(LRC)和无进展生存率(PFS)分别为92%,95%和92%,而3DCRT组则为85%,82%和70%,分别。 OS,LRC和PFS的比较显示,IMRT和3DCRT之间没有显着差异。与3DCRT相比,IMRT的2年或更高级别的慢性胃肠道(GI)并发症的3年累积发生率显着降低(3%vs. 45%,p?340 mL(3%vs. 45%,p?<?)。 001)。IMRT治疗的患者发生3级急性血液学并发症的发生率较高(p 。05)。小肠loop或肠袋的V40和V45可以预测急性和慢性胃肠道并发症的发生。我们的结果表明,IMRT辅助治疗宫颈癌对于减少胃肠道并发症而不增加预后很有帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号